I lead the Connective Tissue Disease programme in the Musculoskeletal Theme of the NIHR Manchester Biomedical Research Centre. My major research focus is on the association between inflammatory rheumatic diseases and premature atherosclerosis / coronary heart disease. In particular, my focus is on long-term outcomes in systemic lupus erythematosus and rheumatoid arthritis. Through my membership of the Systemic Lupus International Collaborating Clinics and the British Isles Lupus Assessment Group, I lead the BILAG Biologics Register and several studies on Metabolic Syndrome in SLE and Long-term damage in SLE. I am also Chief Investigator in the MASTERPLANS Consortium, an MRC-funded SLE Stratified Medicine Consortium.
I am committed to contributing to and participating in important collaborative studies and in the past few years I have been involved in the Wellcome Trust Case Control Consortium and the British Society for Rheumatology Biologics Registry Control Consortium. The studies arising from these collaborations have resulted in important advances in our understanding of the genetic basis of several common disease (WTCCC) as well as our understanding of the safety and long-term efficacy of biologic agents used in RA (BSRBR).
I provide consultancy for several pharmaceutical companies and serve on Data Safety Steering Committees in a number of commercial and academic clinical trials and am Chair of the Astra Zeneca Anifrolumab Global Steering Committee.